-
Armata Pharmaceuticals NYSE MKT LLC:ARMP Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United Statesand Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Location: 4503 Glencoe Ave, California, 90292-6372, US | Website: www.armatapharma.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
216.7M
Cash
26.41M
Avg Qtr Burn
-9.639M
Short % of Float
0.04%
Insider Ownership
70.25%
Institutional Own.
3.82%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AP-PA02 Details Non-Cystic Fibrosis Bronchiectasis | Phase 2 Data readout | |
AP-SA02 Details Bacterial infection | Phase 2a Data readout | |
AP-PA02 Details Cystic fibrosis | Phase 1/2 Update |